{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:19:11Z","timestamp":1794374351876,"version":"4.9.0"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:00:00Z","timestamp":1766188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-025-02510-6","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:01:47Z","timestamp":1766188907000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anti-BCMA CAR-T cells attenuate microglial activation in progressive multiple sclerosis: indicating a plasma cell-microglia crosstalk"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-8056","authenticated-orcid":false,"given":"Fatme S.","family":"Ismail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Melzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,20]]},"reference":[{"key":"2510_CR1","doi-asserted-by":"publisher","unstructured":"Qin, C. et al. Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis. Cell https:\/\/doi.org\/10.1016\/J.CELL.2025.09.020 (2025).","DOI":"10.1016\/J.CELL.2025.09.020"},{"key":"2510_CR2","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Medicine 5, 550\u2013558.e2 (2024).","journal-title":"Medicine"},{"key":"2510_CR3","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000973","volume":"8","author":"G Kumar","year":"2021","unstructured":"Kumar, G. et al. CNS autoimmune responses in BCMA-deficient mice provide insight for the failure of atacicept in MS. Neurol. Neuroimmunol. Neuroinflammation 8, e973 (2021).","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"key":"2510_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen, O. et al. Neurocognitive and hypokinetic movement disorder with features of Parkinsonism following BCMA-targeting CAR-T cell therapy. Nat. Med. 27, 2099 (2021).","journal-title":"Nat. Med."},{"key":"2510_CR5","doi-asserted-by":"publisher","first-page":"3238","DOI":"10.1016\/j.cell.2025.03.041","volume":"188","author":"AC Geraghty","year":"2025","unstructured":"Geraghty, A. C. et al. Immunotherapy-related cognitive impairment after CAR T cell therapy in mice. Cell 188, 3238\u20133258.e25 (2025).","journal-title":"Cell"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02510-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02510-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:01:48Z","timestamp":1766188908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-025-02510-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,20]]},"references-count":5,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2510"],"URL":"https:\/\/doi.org\/10.1038\/s41392-025-02510-6","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,20]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FS.I. reports no conflicts of interest. HP.H. has received honoraria from Boehringer Ingelheim, Merck Darmstadt KgA and Novartis for serving on data monitoring committees, for work not related to the present manuscript. N.M. reported receiving grants from the German Federal Ministry of Education and Research, for work not related to the present manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"407"}}